Drug Trial News

RSS

New drug offers hope for osteoarthritis patients suffering from debilitating hand pain

Osteoarthritis is the most prevalent arthritis worldwide and is characterized by chronic pain and impaired physical function.

13 Nov 2017

Ozanimod effective against multiple sclerosis, enters New Drug Approval process with FDA

Celgene Corporation recently announced results from two phase 3 trials evaluating the efficacy and safety of the drug ozanimod.

10 Nov 2017

New gene therapy trial for X-linked myotubular myopathy offers hope to children

Ann & Robert H. Lurie Children's Hospital of Chicago is one of the few centers participating in ASPIRO, an international Phase 1/2 clinical trial of a gene therapy product called AT132 for X-linked myotubular myopathy – a rare disease characterized by severe muscle weakness, breathing difficulty and early death.

8 Nov 2017

New category of immunotherapy appears safe to use in patients with both cancer and HIV

A new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advanced malignancies and HIV, a population excluded from earlier trials of such therapies, according to an early-phase trial.

7 Nov 2017

FDA approves first targeted cancer treatment based on basket study

The US Food and Drug Administration has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD).

7 Nov 2017

Drug can safely and effectively help infants with SMA gain muscle function, study shows

More than half of the babies with infantile-onset spinal muscular atrophy (SMA) who were treated with nusinersen (Spinraza) gained motor milestones, compared to none of the babies in the control group. Infants treated with the drug also had 63 percent lower risk of death.

6 Nov 2017

Quorum sensing data presented at the North American Cystic Fibrosis Conference by Neem Biotech

Neem Biotech, the Welsh-based fundamental Research and Development arm of the Zaluvida group of life science companies, was pleased to present the work into development of a novel mode of action as an adjunct to existing antibiotics at the North American Cystic Fibrosis Conference Indiana, USA from 2nd November 2017 to 4th of November 2017.

From Neem Biotech 6 Nov 2017

ACADIA Pharmaceuticals announces results from Phase II study of antipsychotic in Alzheimer's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer's disease psychosis at the 10th Clinical Trials on Alzheimer's Disease meeting in Boston.

3 Nov 2017

New treatment reduces disease burden in patients with rare dermatologic condition

A new treatment for a rare and often incurable condition called dermatomyositis (DM) reduced the severity of the disease in patients whose DM was resistant to other therapies.

31 Oct 2017

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya (fingolimod) vs. interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS).

30 Oct 2017

CureVac begins phase I study to assess intratumoral application of RNAdjuvant technology in patients with solid tumors

CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.

28 Oct 2017

Sunovion announces results from Phase 3 clinical study of new drug in children, adolescents with bipolar depression

Sunovion Pharmaceuticals Inc. today announced post-hoc analysis results of a positive Phase 3 placebo-controlled clinical study, as well as interim data from a long-term open-label extension study evaluating Latuda (lurasidone HCI) in children and adolescents (10 to 17 years of age) with major depressive episodes associated with bipolar I disorder (bipolar depression).

28 Oct 2017

Clinical trial shows promising results for treatment of patients with recurrent high-grade glioma

New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.

28 Oct 2017

Study shows efficacy of antipsychotic as adjunctive therapy for gastroparesis in emergency department

Haloperidol is an effective first-line agent in combination with standard analgesic and antiemetic agents for the treatment of gastroparesis in the emergency department.

26 Oct 2017

New molecule could become first treatment against chemotherapy-induced neuropathy

IDIBELL Researchers of the Neuro-Oncology Unit of Bellvitge University Hospital - Catalan Institute of Oncology, led by Dr. Jordi Bruna, have successfully tested a new molecule capable of preventing the development of peripheral neuropathy induced by chemotherapy in cancer patients, especially in colon cancer cases, the third most common neoplasm in the world.

24 Oct 2017

TGen awarded $2.5 million SU2C grant to test new method of treating pancreatic cancer

Stand Up To Cancer has awarded a $2.5 million SU2C CatalystR grant to the Translational Genomics Research Institute to investigate a revolutionary new method of treating pancreatic cancer, one of the most aggressive of all cancers.

13 Oct 2017

Phase 3 clinical trial for compound that shows promise in treatment of Rett syndrome

Rettsyndrome.org is pleased to share that Neuren Pharmaceuticals, today, after meeting with the FDA, will conduct a Phase 3 clinical trial for trofinetide, a compound that shows great promise in the treatment of Rett syndrome, in children and adults.

13 Oct 2017

Salk scientists receive $2.5 million funding to conduct pancreatic cancer clinical study

Salk Professor and HHMI Investigator Ronald Evans has been awarded $2.5 million by Stand Up 2 Cancer (SU2C) as part of a multi-institution team to conduct clinical studies to open up a new avenue for immunotherapy in the treatment of pancreatic cancer.

12 Oct 2017

Clinical trial tests frankincense as potential breast, colon cancer treatment

Cancer surgeon and researcher Nancy DeMore is leading a clinical trial using frankincense to try to treat breast and colon cancer at the Medical University of South Carolina. The study was inspired by a research specialist in DeMore's lab.

11 Oct 2017

Allergy medication restores nervous system function in patients with chronic MS

In a remarkably rapid translation of laboratory research findings into a treatment with the potential to benefit patients, UC San Francisco scientists have successfully completed a Phase II clinical trial showing that an FDA-approved antihistamine restores nervous system function in patients with chronic multiple sclerosis (MS).

11 Oct 2017

Drug Trial News

New drug offers hope for osteoarthritis patients suffering from debilitating hand pain

Ozanimod effective against multiple sclerosis, enters New Drug Approval process with FDA

New gene therapy trial for X-linked myotubular myopathy offers hope to children

New category of immunotherapy appears safe to use in patients with both cancer and HIV

FDA approves first targeted cancer treatment based on basket study

Drug can safely and effectively help infants with SMA gain muscle function, study shows

Quorum sensing data presented at the North American Cystic Fibrosis Conference by Neem Biotech

ACADIA Pharmaceuticals announces results from Phase II study of antipsychotic in Alzheimer's disease psychosis

New treatment reduces disease burden in patients with rare dermatologic condition

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

CureVac begins phase I study to assess intratumoral application of RNAdjuvant technology in patients with solid tumors

Sunovion announces results from Phase 3 clinical study of new drug in children, adolescents with bipolar depression

Clinical trial shows promising results for treatment of patients with recurrent high-grade glioma

Study shows efficacy of antipsychotic as adjunctive therapy for gastroparesis in emergency department

New molecule could become first treatment against chemotherapy-induced neuropathy

TGen awarded $2.5 million SU2C grant to test new method of treating pancreatic cancer

Phase 3 clinical trial for compound that shows promise in treatment of Rett syndrome

Salk scientists receive $2.5 million funding to conduct pancreatic cancer clinical study

Clinical trial tests frankincense as potential breast, colon cancer treatment

Allergy medication restores nervous system function in patients with chronic MS

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News